RxDoctor Payments Data

Felix Millhouse, MD

Interventional Cardiology · Daly City, CANPI 1811912447

Payments from drug & device makers

$15,968in general payments, 2019–2025

Across 508 payments — averaging $31.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$4K
  • Medtronic$3K
  • Boston Scientific$3K
  • Chiesi USA, Inc.$1K
  • Amgen$1K
  • Abbott$526
  • plus $3K from 24 others

What the payments were for

  • Speaking & faculty fees$3,30021%
  • Food & beverage$12,61479%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,968 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$465,841
Medicare patients
469
Services billed
5,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$354,612
EntrestoSacubitril/Valsartan189$250,011
JardianceEmpagliflozin73$78,972
XareltoRivaroxaban31$48,645
Repatha SureclickEvolocumab51$45,502
Repatha PushtronexEvolocumab27$26,066
VerquvoVericiguat12$18,085
Praluent PenAlirocumab20$15,726
FarxigaDapagliflozin Propanediol12$13,640
Atorvastatin Calcium605$12,687
Ranolazine ErRanolazine79$11,457
ClopidogrelClopidogrel Bisulfate451$10,793
Rosuvastatin Calcium294$10,465
Metoprolol Succinate419$7,023
Carvedilol236$4,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$354,612293 claims
NovartisEntresto$492$250,011189 claims
Johnson & JohnsonXarelto$121$48,64531 claims
MerckVerquvo$413$18,08512 claims
AstraZenecaFarxiga$374$13,64012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Daly City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →